GSK plans to roll out a billion doses of its potential Covid
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The world’s largest vaccine company, UK-based GSK, plans to roll out a billion doses of its potential Covid-19 vaccine, being developed in collaboration with vaccine major Sanofi, in the second half of 2021.

• The company will use its well-established ‘adjuvant’ platform, and Sanofi’s protein-based antigen technology both proven platforms, which will allow a quick scale-up of vaccine doses, required globally in a pandemic.

• The company believes `adjuvant’ technologies can reduce the amount of vaccine required per dose, allowing more vaccine doses to be produced, and hence getting more people immunized.

• After clearing clinical trials and regulatory approvals, GSK is confident of supplying a billion doses in 2021.

• The company said in a media presentation on 11 June it was ``too early’’ to speak about pricing of the proposed vaccine, as it was still at the beginning of the collaboration with Sanofi.

Around 15-18 months is considered “a miracle” to roll out a vaccine, and prior research on SARS and MERS, both Corona viruses, has enabled a faster development of the one for SARS-CoV2, according to Emmanuel Hanon, head of R&D, GSK Vaccines. A classical timeline of vaccine discovery and development involves around 10 to 20 years.

Source: https://health.economictimes.indiatimes.com/news/pharma/gsk-plans-to-roll-out-a-billion-doses-of-its-potential-covid-19-vaccine/76312376
Dr. T●●●●z H●●●●●●i and 9 others like this6 shares
Like
Comment
Share